SpyGlass Pharma, Inc. (SGP)
↓ Download CSV| Metric (FY) | 2025 | 2024 | 2023 |
|---|---|---|---|
| Operating Income | -$41.45M | -$27.06M | — |
| Net Income | -$39.87M | -$29.16M | — |
| EPS (Diluted) | $-17.98 | $-16.31 | — |
| Total Assets | $115.87M | $23.32M | — |
| Total Liabilities | $10.17M | $11.25M | — |
| Shareholders' Equity | -$98.84M | -$60.47M | -$32.98M |
| Cash & Equivalents | $96.36M | $16.27M | — |
| Operating Cash Flow | -$32.70M | -$22.03M | — |
| Capital Expenditures | $789.0K | $1.99M | — |
| Shares Outstanding | 2.20M | 2.20M | — |